Keyphrases
Receptor Blockade
100%
Serum Adiponectin
100%
Interleukin-6 Receptor (IL-6R)
100%
People with Obesity
100%
Explanatory Analysis
100%
Placebo
50%
Tocilizumab
50%
Adiponectin
33%
Leptin
33%
Obese Men
33%
Leptin Levels
33%
Interleukin-6
16%
Type 2 Diabetes Mellitus (T2DM)
16%
Exercise Training
16%
Insulin Sensitivity
16%
Serum Samples
16%
In Vitro Study
16%
Human Subjects
16%
In Vitro Experiment
16%
Human Obesity
16%
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
16%
Exercise Training Intervention
16%
Double-blind Clinical Trial
16%
White Adipose Tissue
16%
High-fat Diet Mice
16%
Human Individual
16%
Interleukin-6 Inhibitors
16%
Intravenous Tocilizumab
16%
Medicine and Dentistry
Receptor Blocking
100%
Adiponectin
100%
Interleukin 6 Receptor
100%
Leptin
50%
Tocilizumab
50%
Placebo
37%
Exercise
25%
Interleukin 6
12%
Maturity Onset Diabetes of the Young
12%
Clinical Trial
12%
In Vitro
12%
Insulin Sensitivity
12%
Lipid Diet
12%
Homeostatic Model Assessment
12%
Receptor Antibody
12%
White Adipose Tissue
12%
Human Subject
12%
Immunology and Microbiology
Adiponectin
100%
Interleukin-6 Receptor
100%
Receptor Blocking
100%
Tocilizumab
50%
Exercise
25%
Mouse
12%
Interleukin 6
12%
Insulin Sensitivity
12%
Insulin Resistance
12%
Human
12%
Receptor Antibody
12%
White Adipose Tissue
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adiponectin
100%
Interleukin 6 Receptor
100%
Leptin
50%
Tocilizumab
50%
Placebo
37%
Mouse
12%
Interleukin 6
12%
Non Insulin Dependent Diabetes Mellitus
12%
Clinical Trial
12%
Insulin Resistance
12%
Human
12%
Receptor Antibody
12%
Neuroscience
Adiponectin
100%
Interleukin-6 Receptor
100%
Leptin
50%
Tocilizumab
50%
Placebo
37%
In Vitro
12%
Interleukin 6
12%
Receptor Antibody
12%
White Adipose Tissue
12%